Endocyte: ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

Future-oriented and long-term alliance with Endocyte for the further expansion of targeted radioligand therapy with no-carrier-added Lutetium-177 for prostate cancer patients ITM Isotopen Technolo...